Life science research is increasingly reliant on computation, as affirmed by the recent mapping of the human genome and the analysis questions it poses. Our task is to make sense of these genetic blueprints to develop treatments and therapies for disease. This market is huge, as is the commitment by pharmaceutical companies, biotech firms, and the investment community. The stage is set for scientific discovery and technology advances, the stakes are high, and researchers have many analysis alternatives. The question is whether visualization can be a player in this market and whether it's up to the challenges. This is the question we attempted to answer as panelists at the Visualization 2001 conference. As a group of researchers and practitioners in this burgeoning field, we have noticed three broad problem-solving themes: the visual integration of analyses; high-dimensional analytic visualization; and the emergence of new visualization designs to solve problems. It is clear that advances in information visualization will be integral to bio- and cheminformatics.
[1]
J. Mesirov,et al.
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
,
1999,
Science.
[2]
F. Lombardo,et al.
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
,
2001,
Advanced drug delivery reviews.
[3]
M. Segal,et al.
Relating Amino Acid Sequence to Phenotype: Analysis of Peptide‐Binding Data
,
2000,
Biometrics.
[4]
John Kinney,et al.
Visualization for bio- and chem-informatics: are you being served?
,
2001,
VIS '01.
[5]
Christopher A. Badurek,et al.
Review of Information visualization in data mining and knowledge discovery by Usama Fayyad, Georges G. Grinstein, and Andreas Wierse. Morgan Kaufmann 2002
,
2003
.
[6]
David Page,et al.
KDD Cup 2001 report
,
2002,
SKDD.
[7]
Vladimir Brusic,et al.
MHCPEP, a database of MHC-binding peptides: update 1996
,
1997,
Nucleic Acids Res..